Regulation of cytosolic pattern recognition receptor signaling in macrophages
巨噬细胞胞质模式识别受体信号传导的调节
基本信息
- 批准号:8634013
- 负责人:
- 金额:$ 38.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-03-11 至 2018-02-28
- 项目状态:已结题
- 来源:
- 关键词:AIM2 geneAcuteAdaptor Signaling ProteinAffectBackBacterial InfectionsBindingBiologicalBone MarrowCaspaseCaspase-1ChronicCommunicable DiseasesComplexCytosolDefectDevelopmentDiseaseEquilibriumFailureFamilial Mediterranean FeverFamilyFamily memberFeedbackFrancisella tularensisGene TransferGoalsHealthHomeostasisHost DefenseHumanImmuneImmune System DiseasesImmune responseImmune systemIn VitroInfectionInflammationInflammatoryInheritedInterleukin-1Interleukin-18InvadedLeucine-Rich RepeatLinkMediatingModelingMolecularMusMutationNatural ImmunityNomenclatureNucleotidesPathway interactionsPatientsPatternPattern recognition receptorPositioning AttributeProcessProductionProtein FamilyProteinsReceptor SignalingRecruitment ActivityRegulationResearchRoleSignal TransductionSimulateSmall Interfering RNASterilitySymptomsTestingTimeTissuesTransgenic MiceVaccinia virusViralVirus DiseasesWorkbasecombatcytokinedesignfeedinghuman CASP4 proteinimprovedin vivoinflammatory modulationmacrophagemarenostrinmembermouse modelmutantnovelnovel therapeuticspathogenpreventprocaspase-1public health relevancereceptorresearch studyresponsesecretion processtooltreatment strategy
项目摘要
DESCRIPTION (provided by applicant): Invading pathogens are recognized by pattern recognition receptors (PRRs) of the innate immune system as a first line of defense. Activation of PRRs from the Nucleotide-binding and leucine-rich repeat containing (NLR) protein family and Absent in melanoma 2 (AIM2) in macrophages results in inflammasome formation. Inflammasomes are protein platforms that are essential for the activation of inflammatory Caspases and subsequently for the maturation and release of the pro-inflammatory cytokines interleukin (IL)-1? and IL-18. Assembly of inflammasomes depends on PYRIN domain (PYD)-mediated recruitment of the adaptor protein ASC to activated PRRs, which then recruits pro-Caspase-1. In addition, Caspase-4, -5 and -8 participate. However, the molecular mechanism of inflammasome activation by cytosolic PRRs and in particular, regulation and termination of this process is poorly understood. We discovered a family of small proteins composed of only a PYD, called PYD-containing (PYDC or POP) proteins. We show that PYDCs function to inhibit inflammasome activation by blocking the PYD-PYD interactions essential for inflammasome formation. However, their precise role and contribution to in vivo host defense and inflammatory disease is still unknown. Inflammasomes are essential for host defense; however, inappropriate inflammasome activation also causes excessive and chronic inflammation, tissue destruction and the debilitating symptoms of the growing autoinflammatory diseases. Therefore, a balanced inflammasome response to allow pathogen clearance during acute infection, while preventing systemic inflammation through timely termination, is essential for homeostasis. We hypothesize that it is the role of the PYDC proteins to maintain this balanced inflammasome response through a negative feedback mechanism. Since PYDC proteins are lacking from mice, we generated novel mouse models to simulate the more complex inflammasome regulation evolved in humans. We propose to determine PYDC-mediated inflammasome regulation and termination during all known scenarios of inflammasome activation: pathogen infection/pathogen-associated molecular pattern (PAMP), tissue damage/damage associated molecular pattern (DAMP) and hereditary PRR mutation in macrophages and in vivo. We will focus on select inflammasome-activating PRRs. In aim 1 we will determine the molecular mechanism of inflammasome regulation and termination for each PYDC ex vivo in macrophages and in aim 2 we propose to determine PYDC-mediated inflammasome regulation in vivo. Collectively, our study is designed to establish the specific inflammasome regulatory function of the PYDC family during infection and inflammatory disease, which we expect will significantly advance our understanding of fundamental biological principles underlying innate immunity, host defense and inflammatory disease and the mechanism by which these responses are regulated.
描述(由申请人提供):入侵病原体被先天免疫系统的模式识别受体(PRR)识别,作为第一道防线。在巨噬细胞中,来自核苷酸结合和富含亮氨酸重复序列(NLR)蛋白家族和黑素瘤中缺失2(AIM 2)的PRR的激活导致炎性小体形成。炎性小体是一种蛋白质平台,对炎症性半胱天冬酶的激活以及随后促炎细胞因子白细胞介素(IL)-1(IL-1)的成熟和释放至关重要。IL-18。炎性小体的组装依赖于PYRIN结构域(PYD)介导的衔接蛋白ASC向活化的PRR的募集,其然后募集胱天蛋白酶原-1。此外,Caspase-4、-5和-8也参与其中。然而,炎症小体激活的细胞溶质PRRs的分子机制,特别是,调节和终止这一过程是知之甚少。我们发现了一个由PYD组成的小蛋白家族,称为PYD-含(PYDC或POP)蛋白。我们发现PYDC通过阻断炎性小体形成所必需的PYD-PYD相互作用来抑制炎性小体活化。然而,它们在体内宿主防御和炎性疾病中的确切作用和贡献仍然未知。炎性小体对于宿主防御是必不可少的;然而,不适当的炎性小体激活也会导致过度和慢性炎症、组织破坏和日益增长的自身炎症性疾病的衰弱症状。因此,平衡的炎性小体反应以允许在急性感染期间清除病原体,同时通过及时终止来预防全身性炎症,对于稳态是必不可少的。我们推测PYDC蛋白的作用是通过负反馈机制维持这种平衡的炎性小体反应。由于小鼠缺乏PYDC蛋白,我们产生了新的小鼠模型来模拟人类进化的更复杂的炎性小体调节。我们建议确定PYDC介导的炎性小体调节和终止在所有已知的情况下的炎性小体激活:病原体感染/病原体相关的分子模式(PAMP),组织损伤/损伤相关的分子模式(DAMP)和遗传性PRR突变在巨噬细胞和体内。我们将集中于选择炎性小体激活PRR。在目标1中,我们将确定巨噬细胞中每种PYDC离体炎性小体调节和终止的分子机制,在目标2中,我们提出确定PYDC介导的体内炎性小体调节。总的来说,我们的研究旨在建立PYDC家族在感染和炎性疾病期间的特异性炎性小体调节功能,我们预计这将显著促进我们对先天免疫,宿主防御和炎性疾病的基本生物学原理以及调节这些反应的机制的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christian Stehlik其他文献
Christian Stehlik的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christian Stehlik', 18)}}的其他基金
A Regulatory Checkpoint in the Pathogenesis of Inflammatory Arthritis
炎症性关节炎发病机制的监管检查点
- 批准号:
9844345 - 财政年份:2013
- 资助金额:
$ 38.63万 - 项目类别:
A Regulatory Checkpoint in the Pathogenesis of Inflammatory Arthritis
炎症性关节炎发病机制的监管检查点
- 批准号:
8634025 - 财政年份:2013
- 资助金额:
$ 38.63万 - 项目类别:
Regulation of cytosolic pattern recognition receptor signaling in macrophages
巨噬细胞胞质模式识别受体信号传导的调节
- 批准号:
10356799 - 财政年份:2013
- 资助金额:
$ 38.63万 - 项目类别:
A Regulatory Checkpoint in the Pathogenesis of Inflammatory Arthritis
炎症性关节炎发病机制的监管检查点
- 批准号:
9246985 - 财政年份:2013
- 资助金额:
$ 38.63万 - 项目类别:
A Regulatory Checkpoint in the Pathogenesis of Inflammatory Arthritis
炎症性关节炎发病机制的监管检查点
- 批准号:
8824440 - 财政年份:2013
- 资助金额:
$ 38.63万 - 项目类别:
A Regulatory Checkpoint in the Pathogenesis of Inflammatory Arthritis
炎症性关节炎发病机制的监管检查点
- 批准号:
8480663 - 财政年份:2013
- 资助金额:
$ 38.63万 - 项目类别:
Regulation of cytosolic pattern recognition receptor signaling in macrophages
巨噬细胞胞质模式识别受体信号传导的调节
- 批准号:
8437829 - 财政年份:2013
- 资助金额:
$ 38.63万 - 项目类别:
POP3: a novel inhibitor of endothelial cell activation
POP3:一种新型内皮细胞活化抑制剂
- 批准号:
8109954 - 财政年份:2010
- 资助金额:
$ 38.63万 - 项目类别:
POP3: a novel inhibitor of endothelial cell activation
POP3:一种新型内皮细胞活化抑制剂
- 批准号:
7995154 - 财政年份:2010
- 资助金额:
$ 38.63万 - 项目类别:
Maturation of IL-1beta and IL-18 in novel macrophage aggresomes
新型巨噬细胞聚集体中 IL-1β 和 IL-18 的成熟
- 批准号:
7642202 - 财政年份:2009
- 资助金额:
$ 38.63万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 38.63万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 38.63万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 38.63万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 38.63万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 38.63万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 38.63万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 38.63万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 38.63万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 38.63万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 38.63万 - 项目类别:
Operating Grants